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Introduction
The word ‘surrogate’ is equivalent to ‘substitute’, and strictly a
surrogate end-point should be able to substitute completely
for the end-point of interest; there is, however, much misuse
of the term. This short communication discusses a number of
end-points that appear to have a useful role to play in the
development of new agents, but even they could not be
strictly called surrogates and may be better described as
intermediate end-points.
The reason to seek these intermediates is that they generally
provide earlier information and are easier and cheaper to use.
They are also frequently more ethical to obtain, achieve or
monitor than the clinical end-point, and in addition there are
circumstances in which the surrogate end-point may be
superior to the clinical end-point, in that it assesses the
underlying disease process in a more direct manner [1]. It is
argued below that change in proliferation may be one such
end-point in relation to estimating clinical benefit from new
agents.
Certain dangers must be considered in the application of
supposed surrogates, in that these may not always reflect the
disease process despite all evidence to date indicating that
they do. In addition, the end-point will very often not (and
maybe cannot) capture the overall risk/benefit of a treatment,
but this will normally be readily apparent.
Clinical trial design in early breast cancer
The contemporary performance of adjuvant trials in early
breast cancer requires inclusion of thousands of patients and
years of follow up to deliver the hoped for changes in
recurrence-free survival and overall survival. An example is the
ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial,
which randomly assigned 9,366 patients with follow-up for
2.5 years before the first data were available to indicate that
anastrozole was more effective than either tamoxifen or the
combination [2].
The neoadjuvant IMPACT (Immediate Preoperative ‘Arimidex’
[anastrozole], Tamoxifen, or Arimidex Combined with Tamoxifen)
trial was designed to determine whether either clinical
response or change in the proliferative biomarker Ki67 could
predict the outcome of the ATAC trial. IMPACT required only
330 patients and follow-up of just 12 weeks to provide its
primary end-points [3]. To ensure its close representation of
the ATAC trial, eligibility criteria for patients were as close as
possible to those employed within the adjuvant trial itself. It
was observed that the change in the intermediate endpoint
Ki67, at both 2 weeks and 12 weeks in IMPACT, was greater
for anastrozole than for either tamoxifen or the combination,
with the latter two treatment arms exhibiting very similar
change in proliferation to one another. In contrast, the data on
clinical response indicated no significant difference between
the three arms. Thus, change in the biomarker Ki67, but not
change in tumour size (clinical response), could be seen to
be predictive of the outcome of the adjuvant trial. Although it
is highly unlikely that adjuvant trials could ever be replaced by
such neoadjuvant studies, it is possible that, by their conduct
early in drug development, treatment arms that do not merit
assessment in the adjuvant setting (such as the combination
arm of ATAC proved to be) could be excluded and allow
earlier completion of the trials.
Relationship between change in Ki67 and
response/benefit from treatment
The question of whether change in Ki67 relates closely to
clinical response is one that is frequently asked. In IMPACT
there was a statistically significant association between the
change in Ki67 and objective response when the latter is
expressed in the five categories of progressive disease, no
change, minimal response, partial response and complete
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response [3]. However, the relationship is very weak. Never-
theless, the argument can be made that the change in Ki67
would not be expected to act as a good surrogate for clinical
response, and may in fact be rationalized to be a better
indicator of benefit from treatment than clinical response
itself, as follows.
In a slow growing tumour the application of an effective
treatment would be expected to reduce proliferation and to
lead to shrinkage of the tumour. The same effect on prolifera-
tion in a faster growing tumour may lead to slower growth
and therefore treatment benefit, but this might be observed
and recorded clinically as progressive disease. This would
create a complete disconnect between the change in Ki67
and clinical response. However, the application of the same
treatment in the adjuvant setting would be expected to lead
to improved recurrence-free survival for both types of tumour.
This argument suggests that certain biomarkers would be
expected to be better markers of tumour efficacy than clinical
response.
Change in proliferation and long-term outcome
Pretreatment Ki67, change in Ki67 and on-treatment value of
Ki67 with endocrine treatment are all highly variable and
indicate that biological response to such treatment is a
continuum. Indeed, although we frequently dichotomize
patients as responders and nonresponders on the basis of
change in tumour size, it may be more appropriate to
consider them good or poor responders, because tumour
size change is also a continuous variable. Given that the
pretreatment value of Ki67 is a strong prognostic factor and
that the arguments above indicate that the change in Ki67 is
indicative of benefit from therapy, the 2-week value might be
expected to be an indicator of the patient’s prognosis on that
particular treatment. Further data from the IMPACT Trial
supports this view, with the recurrence-free survival of
patients being more closely predicted by 2-week Ki67 values
than pretreatment values [4]. This has been one of the drivers
behind the development of the POETIC (Perioperative
Endocrine Treatment for Individualized Care) trial, which will
test whether the greater prognostic value of on-treatment
measurement of Ki67 can be confirmed in a larger patient
population and be worthy of regular incorporation into a
patient’s disease management.
Measurement of proliferation
For a biomarker to be incorporated into clinical practice, its
measurement must be sufficiently precise. We have
determined that in pairs of samples taken from a single
tumour at the same time using 14 g core-cut needles, the
variability in Ki67 would require an approximately 50%
difference between two samples for these to be deemed
significantly different from one another with 95% confidence
[5]. Similar analyses, but with a 2-week gap between
biopsies, indicated that there was similar precision and no
systematic difference between the prior and 2-week sample;
this was important to establish, given the possibility that the
taking of the first biopsy might itself have resulted in altered
proliferation in the subsequent biopsy.
The 14 g core-cut biopsies taken in most of our studies may
contain a million or more malignant cells, in contrast to the
1,000 cells that we routinely score in a single section; this
much larger cell population might be assessed by molecular
means in an extract of the core-cut, and this would
theoretically give much greater analytical precision. It remains
to be determined whether the mixed cell population that is
sampled in an extract would give an acceptable estimate of
the proliferation of tumour cells.
When to measure
The mean change in Ki67 at 2 weeks after the start of
aromatase inhibitor or tamoxifen therapy is very similar overall
to that after 12 weeks of treatment [6]. However, there is
clear recovery in proliferation levels in a minority of the
tumours, and this appears to be correlated with increased
levels of HER-2 (human epidermal growth factor receptor-2)
in the pretreatment sample, suggesting that this may repre-
sent early acquired resistance to the endocrine agent. If this
can be proven, it provides an important extension of the use
of neoadjuvant endocrine therapy; in the past we have
rejected the study of acquired resistance in the neoadjuvant
model because clinical progression rarely occurs or is
allowed to occur before surgery. The application of this
surrogate biomarker therefore potentially opens the neo-
adjuvant arena, first to the biological study of acquired
resistance and second to the application of agents with the
aim of avoiding this. This type of rationale underpinned the
design of the anastrozole with/without gefitinib study [7], in
which one arm received gefitinib after an initial 2 weeks of
anastrozole alone. Unfortunately, the apparently poor clinical
responsiveness to gifitinib in this population meant that the
hypothetical use of the model in this manner was not
effectively tested.
Does on-treatment Ki67 also predict
long-term outcome after chemotherapy?
We recently extended our analyses of on-treatment measure-
ment of Ki67 to the estimation of long-term outcome with
chemotherapy [8]. In these studies only those patients who
failed to achieve a pathological complete remission could be
evaluated because estimates of Ki67 in the excision biopsy
were required. Although patients with high Ki67 pretreatment
responded better to the neoadjuvant chemotherapy, these
high pretreatment values indicated a worse outcome for high
Ki67. Of particular note, measurement of Ki67 in the excision
sample exhibited much better prediction of outcome, with
50% of patients in the highest tertile of Ki67 having relapsed
within 18 months, whereas more than 50% of patients in the
lower two tertiles had more than 7 years of relapse-free
survival. To make this observation clinically valuable within the
neoadjuvant chemotherapy setting, such measurement ofPage 3 of 3
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Ki67 would necessarily require earlier measurement than at
excision. As yet, no studies have linked earlier measurement
of Ki67 after starting chemotherapy with long-term outcome.
Conclusion
The measurement of on-treatment proliferation using Ki67
provides a useful tool for speeding development of new
drugs. However, although the principle of on-treatment measure-
ment is likely to remain solid, the end-point for judging
effectiveness is likely to vary markedly between agents.
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